EBITDA for the quarter was $193,000. A very positive number.Cash, beginning of period $6,597,187
Cash, end of period $6,443,401
Adjusted EBITDA for the quarter was $193,000.
Revenues coming in with Covid. Covid revenues expected to remain the same for the next couple quarters and Aristotle revenues are starting. In addition with the aquistion of Care Oncology group we will see revenues from that side of their business too.
And still with $6.5 million in the bank.
It's no wonder the short and distort team is trying so hard. They need shares badly and can't afford a squeeze here. Yet they aren't getting the volume they need. Bad enough they have to attack a cancer detection stock but when its not shaking shares loose that makes them grumpy. LOL